FI941860A - Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys - Google Patents
Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys Download PDFInfo
- Publication number
- FI941860A FI941860A FI941860A FI941860A FI941860A FI 941860 A FI941860 A FI 941860A FI 941860 A FI941860 A FI 941860A FI 941860 A FI941860 A FI 941860A FI 941860 A FI941860 A FI 941860A
- Authority
- FI
- Finland
- Prior art keywords
- mbp
- antimyelin
- colonic
- residues
- nervous system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2053799 | 1991-10-22 | ||
CA002053799A CA2053799C (en) | 1991-10-22 | 1991-10-22 | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
CA9200448 | 1992-10-15 | ||
PCT/CA1992/000448 WO1993008212A1 (en) | 1991-10-22 | 1992-10-15 | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
Publications (3)
Publication Number | Publication Date |
---|---|
FI941860A true FI941860A (fi) | 1994-04-21 |
FI941860A0 FI941860A0 (fi) | 1994-04-21 |
FI111050B FI111050B (fi) | 2003-05-30 |
Family
ID=4148603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI941860A FI111050B (fi) | 1991-10-22 | 1994-04-21 | Keskushermoston pesäkekovettumatauti-aivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin valmistusmenetelmä |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0610446B1 (fi) |
AT (1) | ATE236193T1 (fi) |
AU (1) | AU2750092A (fi) |
CA (1) | CA2053799C (fi) |
DE (1) | DE69232987T2 (fi) |
DK (1) | DK0610446T3 (fi) |
ES (1) | ES2196007T3 (fi) |
FI (1) | FI111050B (fi) |
NO (1) | NO310513B1 (fi) |
NZ (1) | NZ244807A (fi) |
RU (1) | RU2121850C1 (fi) |
WO (1) | WO1993008212A1 (fi) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
SI9520118A (sl) * | 1994-10-25 | 1998-08-31 | Immulogic Pharmaceutical Corporation | Sestavki in zdravljenje multiple skleroze |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
DE69525544T2 (de) * | 1994-11-18 | 2002-08-22 | Neurocrine Biosciences Inc | Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
AU5360796A (en) * | 1995-03-09 | 1996-10-02 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
CA2201841C (en) * | 1997-04-04 | 2010-01-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
WO2005009455A1 (fr) * | 2003-07-29 | 2005-02-03 | Terentiev Alexandr Alexandrovi | Composition de peptides presentant une propriete immunoregulatrice |
KR20120103591A (ko) | 2009-10-12 | 2012-09-19 | 라이프바이오 라보라토리즈 엘엘씨 | 다발성 경화증 치료용 조성물 |
US9326773B2 (en) | 2012-01-26 | 2016-05-03 | Covidien Lp | Surgical device including buttress material |
WO2024094562A1 (en) * | 2022-11-01 | 2024-05-10 | Universität Zürich | Novel mbp peptides and their use in the treatment of multiple sclerosis |
-
1991
- 1991-10-22 CA CA002053799A patent/CA2053799C/en not_active Expired - Lifetime
-
1992
- 1992-10-15 WO PCT/CA1992/000448 patent/WO1993008212A1/en active Search and Examination
- 1992-10-15 EP EP93908754A patent/EP0610446B1/en not_active Expired - Lifetime
- 1992-10-15 AU AU27500/92A patent/AU2750092A/en not_active Abandoned
- 1992-10-15 DE DE69232987T patent/DE69232987T2/de not_active Expired - Lifetime
- 1992-10-15 ES ES93908754T patent/ES2196007T3/es not_active Expired - Lifetime
- 1992-10-15 AT AT93908754T patent/ATE236193T1/de not_active IP Right Cessation
- 1992-10-15 DK DK93908754T patent/DK0610446T3/da active
- 1992-10-15 RU RU94027578A patent/RU2121850C1/ru not_active IP Right Cessation
- 1992-10-20 NZ NZ244807A patent/NZ244807A/xx not_active IP Right Cessation
-
1994
- 1994-04-19 NO NO19941415A patent/NO310513B1/no not_active IP Right Cessation
- 1994-04-21 FI FI941860A patent/FI111050B/fi active
Also Published As
Publication number | Publication date |
---|---|
NO941415L (fi) | 1994-06-22 |
ES2196007T3 (es) | 2003-12-16 |
RU2121850C1 (ru) | 1998-11-20 |
CA2053799C (en) | 2002-03-12 |
DE69232987T2 (de) | 2004-01-29 |
AU2750092A (en) | 1993-05-21 |
EP0610446B1 (en) | 2003-04-02 |
ATE236193T1 (de) | 2003-04-15 |
FI941860A0 (fi) | 1994-04-21 |
WO1993008212A1 (en) | 1993-04-29 |
DK0610446T3 (da) | 2003-07-14 |
CA2053799A1 (en) | 1993-04-23 |
NO310513B1 (no) | 2001-07-16 |
EP0610446A1 (en) | 1994-08-17 |
RU94027578A (ru) | 1996-10-20 |
FI111050B (fi) | 2003-05-30 |
NZ244807A (en) | 1997-08-22 |
DE69232987D1 (de) | 2003-05-08 |
NO941415D0 (no) | 1994-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
FI941860A0 (fi) | Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys | |
PT792287E (pt) | Analogos peptidicos da proteina basica da mielina humana | |
ES2159322T3 (es) | Especificidad de peptidos de anticuerpos anti-proteina basica de la mielina y administracion de peptidos de la proteina basica de la mielina a pacientes con esclerosis multiple. | |
HUT62916A (en) | Process for producing immunogenic peptides and pharmaceutical compositions comprising same | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
IL116559A0 (en) | Chimeric proteins | |
WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
DK1394178T3 (da) | Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment | |
NZ335835A (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |